Skip to main content
OpenTrials
Completed

NCT Number: NCT05849181

Localized Body Cooling Technology on Sleep and Metabolism in African, American With Overweight and Obesity

The goal of this study is to see the effect that a cooling pillow pad called Moona has on sleep quality.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Chicago

Chicago, Illinois, 60637, United States

About this study

Obesity and diabetes pose a significant burden on healthcare systems worldwide. Evidence from large cross-sectional and longitudinal epidemiologic studies, and well-designed experimental sleep manipulations, demonstrated that insufficient sleep is a risk factor for obesity-induced insulin resistance and type 2 diabetes. Limited available evidence suggests that optimizing sleep duration and quality in individuals who experience deficient sleep could have beneficial effects on weight maintenance, facilitate weight loss and improve glucose metabolism. It is well known that body temperature impacts sleep. A rapid decline in core body temperature increases the likelihood of sleep initiation and may facilitate an entry into the deeper stages of sleep.

Pharmacological treatment is often prescribed for sleep disturbances, primarily insomnia. But sleep extension with benzodiazepines/sedative-hypnotic agents does not appear to have beneficial effects on metabolism, in fact, these drugs may even have an adverse effect on glucose metabolism. Many people use melatonin as a sleep aid, however, the available data do not support a major role of melatonin in body weight regulation and the evidence supporting melatonin administration in improving glucose metabolism has been mixed.

Limited studies suggest that localized cooling could represent a non-pharmacological strategy to favor sleep onset or improve sleep duration and/or quality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • African American men and women
  • Aged 21-50 years
  • BMI ≥ 27 to 45 kg/m2
  • Self-report of short or poor sleepers (>5 < 7hrs /night and/or a score > 5 on the PSQI),
  • Sleeping between 22:00 and 08:00.
  • Ability to provide informed consent before any trial-related activities
  • Controlled hypertension or dyslipidemia.

Exclusion criteria

  • Previous diagnosis or reveled during the screening PSG (Polysomnography) of obstructive sleep apnea (AHI≥30) or other sleep disorders based on DSM-V (Diagnostic and Statistical Manual of Mental Disorders, fifth edition) criteria.
  • Shift work
  • Diagnosis of diabetes based on history or screening tests
  • History of cognitive or other neurological disorders
  • History of major psychiatric disorder based on DSM-V criteria
  • Presence of unstable or serious medical conditions
  • Use within the past month of melatonin, psychoactive, hypnotic, stimulant or pain medications (except occasionally)
  • Caffeine consumption of greater than 500 mg per day
  • Medically managed weight loss program within the past 6 months
  • History of bariatric weight loss surgery.
  • Women who are pregnant, plan on becoming pregnant, are breastfeeding,
  • Men or women who have a child at home that does not sleep through the night.
  • Active drug/alcohol dependence or abuse

Treatment and study plan

Moona Device

Device

Moona Device pillow pad

Inactive Moona Device

Device

Inactive Moona Device pillow pad

Primary outcomes

  1. Sleep Outcome-Time to sleep onset

    Time frame: Baseline to Day 22

    A decrease in time to sleep onset from baseline to day 22 measured in time of day by Wrist Actigraphy Monitoring.

  2. Sleep Outcome- Wake time

    Time frame: Baseline to Day 22

    Change in wake time from baseline to day 22 measured in time of day by Wrist Actigraphy Monitoring.

  3. Sleep Outcome- Sleep microarousals

    Time frame: Baseline to Day 22

    Change in wake time from baseline to day 22 measured by polysomnography. The index is generated by polysomnography software.

  4. Sleep Outcome- Sleep duration

    Time frame: Baseline to Day 22

    Change in Sleep duration from baseline to day 22 measured in minutes by Wrist Actigraphy Monitoring.

  5. Change in Sleep duration from baseline to day 22

    Time frame: Baseline to Day 22

    Sleep duration measured in minutes by polysomnography.

  6. Sleep Outcome- Regularity of sleep

    Time frame: Baseline to Day 22

    Change in regularity of sleep from baseline to day 22 measured by Wrist Actigraphy Monitoring. The value is from standard deviation of time of middle of the sleep period.

  7. Sleep Outcome- Sleep efficiency

    Time frame: Baseline to Day 22

    Change in sleep efficiency from baseline to day 22 measure by a percentage of total sleep time/time in bed from Wrist Actigraphy Monitoring.

  8. Change in sleep efficiency from baseline to day 22

    Time frame: Baseline to Day 22

    Sleep efficiency measure by a percentage of total sleep time/time in bed from polysomnography.

  9. Change in glucose homeostasis after 22 days of Moona Device usage.

    Time frame: through study completion, an average of 1 month

    The Matsuda Index of whole body insulin sensitivity, the homeostasis model assessment (HOMA) measures beta cell function and insulin resistance. These changes in glucose homeostasis from baseline to 22 days of Moona Device usage are measured by Oral glucose tolerance test (OGTT).

Secondary outcomes

  1. Changes from baseline through day 22 of novel Patient Reported Outcome instrument

    Time frame: Baseline to Day 22

    Detection of within-patient changes in sleep effects reported in a novel Patient-Reported Outcome instrument between baseline and Day 22.

  2. Changes in the perception of sleep quality from baseline through day 22

    Time frame: Baseline to Day 22

    Detection of within-patient change in the perception of sleep quality reported in a novel Patient-Reported Outcome instrument between baseline and Day 22.

  3. Pre-sleep and durational sleep secretion of melatonin values at days 7-8 and days 21-22.

    Time frame: through study completion, an average of 1 month

    Urine samples will be collected at two timepoints before bedtime and in the morning. The secretion of melatonin at these timepoints will result in a numerical value.

  4. Glucose Homeostasis-First phase insulin response

    Time frame: Baseline to Day 22

    Changes in first phase insulin response (ARIg=mu.i^-1.min) from baseline to Day 22 measured by oral glucose tolerance test (OGTT).

  5. Glucose Homeostasis-Oral disposition index (DIo)

    Time frame: Baseline to Day 22

    Changes in oral disposition index (DIo) from baseline to Day 22 measured in (SI x ARIg = [(mu/l)^-1.min^-1] * [mu.l^-1.min]) by oral glucose tolerance test (OGTT).

  6. Glucose Homeostasis- insulinogenic index

    Time frame: Baseline to Day 22

    Changes in insulinogenic index (change in plasma insulin/change in plasma glucose from 0-30 minutes = (pmol/L)/(mg/dL)) from baseline to Day 22 measured by oral glucose tolerance test (OGTT).

  7. Glucose Homeostasis- Mean Absolute Glucose

    Time frame: Baseline to Day 22

    Changes in Mean Absolute Glucose (MAG - mg/dl) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).

  8. Glucose Homeostasis- Coefficient of Variation

    Time frame: Baseline to Day 22

    Changes in Coefficient of Variation (CV - mg/dl) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).

  9. Glucose Homeostasis- Standard Deviation

    Time frame: Baseline to Day 22

    Changes in Standard Deviation (SD-mg/dl) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).

  10. Glucose Homeostasis- Area Under the Curve

    Time frame: Baseline to Day 22

    Changes in Area Under the Curve (AUC - mg/dl) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).

  11. Glucose Homeostasis- Time Spent in Range

    Time frame: Baseline to Day 22

    Changes in Time Spent in Range (TIR - minutes) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).

  12. Glucose Homeostasis- Continuous Overall Net Glycemic Action

    Time frame: Baseline to Day 22

    Changes in Continuous Overall Net Glycemic Action (CONGA - (mg/dl) per minutes) from baseline to Day 22 measured by Continuous Glucose Monitoring System (CGMS).

  13. Glucose-stimulated insulin release inhibition of lipolysis, measured by free fatty acids (FFA) value and oral glucose tolerance test (OGTT).

    Time frame: through study completion, an average of 1 month

    The rate of FFA decline will be estimated as a measure of insulin sensitivity at the level of the adipocyte.

  14. Area under the curve Glucose-dependent insulinotropic polypeptide (GIP) concentrations glucose-dependent insulinotropic polypeptide (GIP) concentrations by oral glucose tolerance test (OGTT).

    Time frame: through study completion, an average of 1 month

    GIP levels, secreted by the K cells in the small intestine is an incretin hormone that is released in response to food ingestion and stimulates insulin release. The OGTT will provide these GIP levels.

  15. Weight in kg, measured from screening through study completion.

    Time frame: through study completion, an average of 1 month

    The change in weight values will be measured by blind scales and anthropometrics measurements.

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Registry information

Official study title

Randomized Double-Blind Pilot Study to Examine the Effects of a Localized Body Cooling Technology on Sleep and Metabolism in African, American With Overweight and Obesity

Acronym: Moona

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 8, 2023
Registry last updated
Sep 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.